OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$2.09
-0.02 (-1.18%)
▼
5d:
-10.13%
30d:
-10.9%
90d:
+42.81%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OABI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OABI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $2.08, which is considered oversold relative to its 30-day fair value range of $2.17 to $2.46.
Technical Outlook: Technically, OABI is in a uptrend. The price is currently testing key support at $2.26. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.33 (+247.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OABI is in a uptrend. The price is currently testing key support at $2.26. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.33 (+247.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.17 -
$2.46
Company Quality Score
57/100
(HOLD)
Options IV Signal
49th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 49th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 247.5% below Wall St target ($7.33)
- WARNING: Recommendation downgraded due to -10.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.17 -
$2.46
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.42
(20.3%)
Support & Resistance Levels
Support Level
$2.26
Resistance Level
$2.79
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.54
Wall Street Target
$7.33
(+247.5%)
Revenue Growth (YoY)
247.3%
Profit Margin
-187.6%
Share & Embed Analysis
Last updated: July 14, 2026 11:43 AM ET
Data refreshes hourly during market hours. Next update: 12:43 PM
Data refreshes hourly during market hours. Next update: 12:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
